The FDA has approved Merck’s Keytruda in combination with chemotherapy for the first-line treatment of malignant pleural mesothelioma (MPM). This approval marks the first indication for Keytruda in MPM in the U.S. and is based on clinical trial data showing significant improvements in overall survival and progression-free survival compared to chemotherapy alone.
Merck & Company (MRK) stock is experiencing a surge today after the company announced it has finalized negotiations with the pan-Canadian Pharmaceutical Alliance for its drug WELIREG. This agreement paves the way for WELIREG to be publicly reimbursed in Canada, a significant step forward for the drug’s accessibility in the country.
Merck & Co Inc has discontinued two Phase 3 trials evaluating Keytruda (pembrolizumab) for the treatment of non-small cell lung cancer and cutaneous squamous cell carcinoma. The decision was based on recommendations from independent Data Monitoring Committees, which found that Keytruda did not demonstrate a statistically significant improvement in survival or recurrence-free survival compared to placebo.
